Atevirdine
Atevirdine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that was under development for the treatment of HIV and AIDS. It was developed by Pharmacia & Upjohn but its development was discontinued in the late 1990s due to poor clinical results.
History[edit]
Atevirdine was first synthesized in the early 1990s as part of a research program by Pharmacia & Upjohn to develop new treatments for HIV and AIDS. The drug was designed to inhibit the reverse transcriptase enzyme, which is crucial for the replication of the HIV virus.
Mechanism of Action[edit]
Atevirdine is a non-nucleoside reverse transcriptase inhibitor (NNRTI). NNRTIs work by binding to the reverse transcriptase enzyme, preventing it from converting viral RNA into DNA. This stops the virus from replicating and spreading to new cells.
Clinical Trials[edit]
Atevirdine underwent several phases of clinical trials in the 1990s. However, the results were disappointing. The drug was found to be less effective than other NNRTIs, and it had a high rate of side effects, including rash and liver toxicity. As a result, Pharmacia & Upjohn decided to discontinue the development of the drug.
Legacy[edit]
Despite the failure of Atevirdine, the research program that produced it contributed to the development of other NNRTIs that have been successful in treating HIV and AIDS. These include Efavirenz, Nevirapine, and Delavirdine.
See Also[edit]
This HIV related article is a stub. You can help WikiMD by expanding it.
Sponsored Health Resource
W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
Medical weight loss NYC | Affordable GLP-1 injections NYC | Budget GLP-1 weight loss shots Philadelphia | New Jersey medical weight loss | NYC medical weight loss | Philadelphia medical weight loss | Sleep clinic NYC | W8MD's Philadelphia GLP-1 doctor | Weight loss prescriptions NYC
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
